High Throughput Sequencing Instruments Capable
of Transforming Genomics to Improve Human Health at an
Unprecedented Scale
Illumina, Inc. (NASDAQ: ILMN), the global leader in
next-generation sequencing technology, today introduced the
NovaSeqTM Series, a new and scalable sequencing architecture
expected one day to enable a $100 genome. Unveiled at the J.P.
Morgan Healthcare Conference, this platform redefines high
throughput sequencing with unrivaled throughput, ease of use, low
per sample costs, and unmatched flexibility.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20170109006363/en/
Illumina NovaSeq 6000 System (Photo:
Business Wire)
NovaSeq is the most powerful sequencer Illumina has ever
launched and will open new horizons for more highly powered
experiments at the depth required to discover rare genetic
variants. It was designed from the ground up to allow a broad set
of researchers to access next-generation sequencing technology and
more easily conduct large-scale genomics projects with greater
sample volumes, or more breadth and depth in the genome. In
addition to a single instrument capable of sequencing from three to
48 human whole genomes per run, the NovaSeq Systems will open up
new markets by making routine a wide range of applications from
ultra-deep sequencing of matched tumor-normal pairs, to large-scale
variant discovery studies associated with complex diseases, and
low-pass sequencing of seed banks to select for specific
traits.
“We are excited to be among the first to incorporate Illumina’s
new NovaSeq System into the HLI sequencing center to complement our
existing HiSeq X® Systems,” said J. Craig Venter, PhD, Co-founder
and Executive Chairman of Human Longevity Inc. “Faster, inexpensive
and innovative sequencing technology is a key component driving
breakthroughs in precision medicine. This technology is also
enabling HLI to expand the HLI database, the world’s most
comprehensive database of genomic, phenotypic, and clinical
data.”
“NovaSeq is a key development for clinical research,” said
Richard Gibbs, Founder of the Baylor College of Medicine Human
Genome Sequencing Center. “We are looking forward to generating
tens of thousands of human whole genomes as we begin genome
translation in earnest.”
“The Regeneron Genetics Center has sequenced more than 150,000
exomes in the last few years and we anticipate that moving to the
NovaSeq platform will further increase our efficiency and output,”
said Aris Baras, MD, Head, Regeneron Genetics Center. “We
believe that genetic insight is critical to informing and advancing
new treatments and are committed to expediting these advances for
patients.”
“The introduction of NovaSeq marks one of the most important
inflection points of innovation in Illumina’s history. In the same
way that HiSeq X enabled the $1,000 genome with the HiSeq®
architecture first announced in 2010, we believe that future
systems derived from the NovaSeq architecture we are launching
today one day will enable the $100 genome and propel discoveries
that will enable a deeper understanding and better treatments for
complex disease,” said Francis deSouza, President and CEO of
Illumina. “The NovaSeq Systems enable the study of genetic links
between health and disease at an unprecedented scale by making it
possible to sequence more samples at greater depth and take on
projects that would otherwise be cost-prohibitive. By accelerating
the trajectory of genomics with these systems, Illumina is making
it possible to envision a future in which all people can benefit
from precision medicine.”
The NovaSeq Series includes the NovaSeq 5000 and 6000 Systems.
These instruments offer ease of use features similar to those found
in Illumina’s desktop sequencing portfolio, including automated
onboard cluster generation, cartridge-based reagents, and
streamlined workflows. With scalable throughput, users will have
the flexibility to perform sequencing applications requiring
different levels of output by simultaneously running one or two
flow cells from up to four different flow cell types.
The NovaSeq 5000 and 6000 Systems are priced at $850,000 and
$985,000 respectively. Compared with other Illumina sequencing
systems, both have lower per sample consumable costs for most
sequencing applications. They provide laboratories that cannot
afford the capital cost of a HiSeq X Five or HiSeq X Ten System
with a roadmap to completing human whole-genome sequencing projects
at a cost of $1,000 per genome.
The NovaSeq 6000 will begin shipping in March 2017 and NovaSeq
5000 will begin shipping mid-2017. For more information, visit
www.illumina.com/novaseq.
For Research Use Only. Not for use in diagnostic
procedures.
About Illumina
Illumina is improving human health by unlocking the power
of the genome. Our focus on innovation has established us as the
global leader in DNA sequencing and array-based technologies,
serving customers in the research, clinical and applied markets.
Our products are used for applications in the life sciences,
oncology, reproductive health, agriculture, and other emerging
segments. To learn more, visit www.illumina.com and
follow @illumina.
Illumina Forward-Looking Statements
This release contains forward-looking statements that involve
risks and uncertainties, such as Illumina’s expectations regarding
the launch of any products and the future cost of genome
sequencing. Among the important factors that could cause actual
results to differ materially from those in any forward-looking
statements are (i) our ability to further develop and commercialize
our instruments and consumables and to deploy new products,
services, and applications, and expand the markets, for our
technology platforms; (ii) our ability to manufacture robust
instrumentation and consumables; (iii) achievement and timing of
the planned deconsolidation of GRAIL, Inc.’s financial results in
our financial statements; (iv) our ability to successfully identify
and integrate acquired technologies, products, or businesses; (v)
our expectations and beliefs regarding future conduct and growth of
the business and the markets in which we operate; (vi) challenges
inherent in developing, manufacturing, and launching new products
and services; and (vii) the application of generally accepted
accounting principles, which are highly complex and involve many
subjective assumptions, estimates, and judgments, together with
other factors detailed in our filings with the Securities and
Exchange Commission, including our most recent filings on Forms
10-K and 10-Q, or in information disclosed in public conference
calls, the date and time of which are released beforehand. We
undertake no obligation, and do not intend, to update these
forward-looking statements, to review or confirm analysts’
expectations, or to provide interim reports or updates on the
progress of the current quarter.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170109006363/en/
Illumina, Inc.Investors:Rebecca
Chambers858-255-5243rchambers@illumina.comorMedia:Gwen
Gordon858-882-6822pr@illumina.com
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Mar 2024 to Apr 2024
Illumina (NASDAQ:ILMN)
Historical Stock Chart
From Apr 2023 to Apr 2024